Back to search results

PET Imaging for Progressive Prostate Cancer

This study is investigating whether special PET scans using [18F]-Fluoro-2-Deoxy-D-Glucose (FDG) and -[18F] Dihydro-Testosterone (FDHT) can better find where prostate cancer has spread in your body. These scans are a type of X-ray test that uses a small amount of a radioactive tracer. The study aims to see how FDHT collects in the body and if its location matches findings from other imaging tests like bone scans, CT scans, and MRI scans. You may be able to join if you are a man with prostate cancer that is getting worse, shown by new lesions on imaging or an increase in measurable soft tissue disease. The study is looking to enroll 300 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 300 men.
What's involved
You will undergo PET scans using FDHT alone or FDG and FDHT at baseline, week 4, week 12, and every 12 weeks of treatment, for up to 8 scans in a 12-month period.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured at baseline, 4 weeks, and 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00588185

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

Recruiting
NAAll AgesInterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~300 participants
Updated 2026-04-09 on ClinicalTrials.gov
What's tested:[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To study the accumulation and biodistribution of FDHT in patients with progressive prostate cancer. The accumulation and location of FDHT activity will be assessed on a site by site basis and correlated with radionuclide bone scan, CT and MRI.
Measured over Baseline, 4 weeks and 12 weeks

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Michael Morris, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Michael Morris, M.D., PH.D.
646-422-4469
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with histologically confirmed prostate cancer.
Progressive disease manifest by either:
Imaging modalities:
Bone Imaging: New osseous lesions on bone imaging (bone scintigraphy or NaF PET scan) and/or MRI or CT: An increase in measurable soft tissue disease, or the appearance of new sites of disease. Or
Biochemical progression: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart.
Visible lesions by either CT, bone imaging, or MRI consistent with disease.
Informed consent.

Exclusion

Previous anaphylactic reaction to either FDHT or FDG
Hepatic: Bilirubin \> 1.5 x upper limit of normal (ULN), AST/ALT \>2.5 x ULN, albumin \< 2 g/dl, and GGT \> 2.5 x ULN IF Alkaline phosphatase \> 2.5 x ULN
Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min

What this trial measures

  • To study the accumulation and biodistribution of FDHT in patients with progressive prostate cancer. The accumulation and location of FDHT activity will be assessed on a site by site basis and correlated with radionuclide bone scan, CT and MRI.Baseline, 4 weeks and 12 weeks